Biofrontera Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BFRI research report →
Companywww.biofrontera.us.com
Biofrontera Inc. , a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp.
- CEO
- Hermann Luebbert
- IPO
- 2021
- Employees
- 92
- HQ
- Woburn, MA, US
Price Chart
Valuation
- Market Cap
- $9.69M
- P/E
- -0.85
- P/S
- 0.22
- P/B
- 1.55
- EV/EBITDA
- -1.34
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 82.79%
- Op Margin
- -20.64%
- Net Margin
- -25.66%
- ROE
- -476.72%
- ROIC
- -62.07%
Growth & Income
- Revenue
- $41.70M · 11.80%
- Net Income
- $-10,536,000 · 40.67%
- EPS
- $-1.04 · 67.70%
- Op Income
- $-9,148,000
- FCF YoY
- -29.36%
Performance & Tape
- 52W High
- $1.19
- 52W Low
- $0.54
- 50D MA
- $0.98
- 200D MA
- $0.91
- Beta
- 0.91
- Avg Volume
- 174.00K
Get TickerSpark's AI analysis on BFRI
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 4, 26 | Weber Kevin Daniel | other | 20,000 |
| Mar 5, 26 | Luebbert Hermann | other | 137,500 |
| Mar 4, 26 | Luebbert Hermann | other | 125,000 |
| Mar 4, 26 | Luebbert Hermann | other | 125,000 |
| Mar 5, 26 | Luebbert Hermann | other | 137,500 |
| Mar 5, 26 | Leffler Eugene Frederick | other | 87,500 |
| Mar 4, 26 | Leffler Eugene Frederick | other | 62,500 |
| Mar 4, 26 | Leffler Eugene Frederick | other | 62,500 |
| Mar 5, 26 | Leffler Eugene Frederick | other | 87,500 |
| Mar 4, 26 | Lanckriet Heikki | other | 20,000 |
Our BFRI Coverage
We haven't published any research on BFRI yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BFRI Report →